Literature DB >> 2885877

Cerebrospinal fluid amino acid concentrations in chronic schizophrenia.

E R Korpi, C A Kaufmann, K M Marnela, D R Weinberger.   

Abstract

The concentrations of the excitatory amino acid, glutamate, the inhibitory amino acids, glycine and taurine, and the inactive amino acids, glutamine and alanine, were determined in cerebrospinal fluid samples from 12 neurological control and 17 chronic schizophrenic patients. No significant differences were observed in any amino acid between the study groups. Within the schizophrenic group, no differences were observed between paranoid and undifferentiated patients. The concentrations of these amino acids in samples obtained from six schizophrenic patients during drug-free as compared to haloperidol-treatment periods also did not differ. These results do not support the glutamate hypothesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885877     DOI: 10.1016/0165-1781(87)90095-3

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

2.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

4.  Elevated gamma-aminobutyric acid levels in chronic schizophrenia.

Authors:  Dost Ongür; Andrew P Prescot; Julie McCarthy; Bruce M Cohen; Perry F Renshaw
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

5.  Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics.

Authors:  A E Evins; E T Amico; V Shih; D C Goff
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

7.  Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice.

Authors:  Suzanne A Brody; Mark A Geyer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 8.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

9.  GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes.

Authors:  Zhe Yu; Qi Fang; Xian Xiao; Yi-Zhi Wang; You-Qing Cai; Hui Cao; Gang Hu; Zhong Chen; Jian Fei; Neng Gong; Tian-Le Xu
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.